Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing (scientific article published on 24 August 2016)

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

Q28303718

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

Q29395525

Detection of circulating tumor DNA in early- and late-stage human malignancies

Q29615778

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

Q29620083

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.

Q33590850

CA 125: the past and the future

Q33608456

PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing

Q33740638

Frequent KIT mutations in human gastrointestinal stromal tumors

Q33985734

Cell-free nucleic acids as biomarkers in cancer patients

Q34184393

Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.

Q34278191

Cancer heterogeneity: implications for targeted therapeutics

Q34321565

Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status

Q34473831

Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)

Q34515855

Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing

Q35142605

Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing

Q35156166

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.

Q35591583

Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing.

Q36185551

Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping

Q37114899

Quantification of free circulating DNA as a diagnostic marker in lung cancer

Q38350044

The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours

Q39512984

PET/CT Imaging in Oncology: Exceptions That Prove the Rule

Q41910787

DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.

Q43540280

Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study.

Q51122492

Circulating free DNA concentration is an independent prognostic biomarker in lung cancer.

Q51581286

Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.

Q54391726

Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnosis and Prognosis

Q58053698

Plasma DNA microsatellite panel as sensitive and tumor‐specific marker in lung cancer patients

Q73294049

Disease recurrence after resection for stage I lung cancer

Q73794196

Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas

Q85049473

P275

Creative Commons Attribution 4.0 International

copyrighted

language of work or name

English

Q1860

P921

main subject

non-small-cell lung carcinoma

Q3658562

P304

page(s)

31985

P577

publication date

2016-08-24

P1433

published in

Scientific Reports

Q2261792

P1476

title

Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing

P478

volume

Reverse relations

cites work (P2860)

Q91344826	Aluminosilicate Nanocomposite on Genosensor: A Prospective Voltammetry Platform for Epidermal Growth Factor Receptor Mutant Analysis in Non-small Cell Lung Cancer
Q91839471	Analysis of solid tumor mutation profiles in liquid biopsy
Q91809618	Assessing the Concordance of Genomic Alterations between Circulating-Free DNA and Tumour Tissue in Cancer Patients
Q99582653	Biomarkers predictive value in early stage non-small cell lung cancer
Q96135270	Blood-based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Pancreatic Cancer and its Value to Guide Clinical Treatment
Q46917029	Circulating DNA in EGFR-mutated lung cancer
Q39197920	Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer.
Q37629653	Circulating and tissue biomarkers in early-stage non-small cell lung cancer
Q53721511	Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns.
Q89143210	Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients
Q61451665	Circulating tumor DNA detection: A potential tool for colorectal cancer management
Q99603571	Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response
Q90505053	Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation
Q90091304	Comparison of Target Enrichment Platforms for Circulating Tumor DNA Detection
Q40489550	Correlation Between Circulating Tumor DNA Levels and Response to Tyrosine Kinase Inhibitors (TKI) Treatment in Non-Small Cell Lung Cancer
Q47109269	Detection of somatic variants and EGFR mutations in cell-free DNA from non-small cell lung cancer patients by ultra-deep sequencing using the ion ampliseq cancer hotspot panel and droplet digital polymerase chain reaction
Q48521971	Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective.
Q50043988	Dynamic changes of circulating tumour DNA in surgical lung cancer patients: protocol for a prospective observational study
Q44323391	EFHD2 promotes epithelial-to-mesenchymal transition and correlates with postsurgical recurrence of stage I lung adenocarcinoma
Q90735910	Evaluation of Two EGFR Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer
Q55248174	GGO and minimally invasive adenocarcinomas: how to deal with?
Q47563363	Incorporating Blood-based Liquid Biopsy Information into Cancer Staging: Time for a TNMB System?
Q49740946	Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer
Q92509170	Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to detect recurrence in gastric cancer
Q64914336	Monitoring of circulating tumor DNA and its aberrant methylation in the surveillance of surgical lung Cancer patients: protocol for a prospective observational study.
Q48163413	Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.
Q55004197	Mutation detection using plasma circulating tumor DNA (ctDNA) in a cohort of asymptomatic adults at increased risk for cancer.
Q47159366	New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.
Q94453247	Optimizing molecular residual disease detection using liquid biopsy postoperatively in early stage lung cancer
Q91651645	Perspectives of the Application of Liquid Biopsy in Colorectal Cancer
Q53688649	Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients.
Q54340242	Role of circulating tumor DNA in the management of early-stage lung cancer.
Q53700833	Sequencing of circulating tumor DNA for dynamic monitoring of gene mutations in advanced non-small cell lung cancer.
Q52346019	The characteristics of ctDNA reveal the high complexity in matching the corresponding tumor tissues.
Q42643276	The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer
Q33697983	The feasibility of using mutation detection in ctDNA to assess tumor dynamics
Q90079694	Ultrasensitive DNA hypermethylation detection using plasma for early detection of NSCLC: a study in Chinese patients with very small nodules
Q92642152	Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
Q37709371	Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer
Q47893937	Utility of urinary circulating tumor DNA for EGFR mutation detection in different stages of non-small cell lung cancer patients

P356	DOI	10.1038/SREP31985
P8608	Fatcat ID	release_y4vjb5f3orb7jmgr35fxxli5bi
P932	PMC publication ID	4995492
P698	PubMed publication ID	27555497